## PREVIOUS THERAPY (Note 1)

- Information not provided
- Not administered
- Administered (select all that apply)
  - Surgery
  - Chemotherapy
  - Radiotherapy
  - Targeted therapy, specify if available
  - Immunotherapy, specify if available

## OPERATIVE PROCEDURE (select all that apply) (Note 2)

- Not specified
- Biopsy (excisional, incisional, core needle), specify
- Resection
  - Glossectomy, specify
  - Buccal mucosa, specify
  - Lip, specify
  - Mandibullectomy, specify
  - Maxillectomy, specify
  - Palatectomy, specify
  - Neck (lymph node) dissection, specify
  - Other, specify

## TUMOUR SITE (select all that apply) (Note 3)

- Not specified
- Lip
  - Mucosal (wet), upper lip
  - Mucosal (wet), lower lip
- Oral cavity
  - Lateral border of tongue
  - Ventral surface of tongue, NOS
  - Dorsal surface of tongue and anterior two-thirds of tongue, NOS
  - Floor of mouth, NOS
  - Hard palate
  - Buccal mucosa (inner cheek)
  - Retromolar trigone
  - Vestibule of mouth
    - Maxillary
    - Mandibular
  - Alveolar process and gingiva
    - Maxillary
    - Mandibular
    - Other
  - Other, specify
### TUMOUR LATERALITY (select all that apply)

- Not specified
- Left
- Right
- Midline

### TUMOUR FOCALITY (Note 4)

- Unifocal
- Bilateral
- Multifocal

Specify number of tumours

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### TUMOUR DIMENSIONS (select all that apply) (Note 5)

Maximum tumour dimension (largest tumour) (pathology and/or imaging determination)

<table>
<thead>
<tr>
<th>mm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

Additional dimensions (largest tumour)

<table>
<thead>
<tr>
<th>mm</th>
<th>mm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Cannot be assessed, specify

### HISTOLOGICAL TUMOUR TYPE (select all that apply) (Note 7)

(Value list based on the World Health Organization Classification of Head and Neck Tumours (2023))

- Squamous cell carcinomas and subtypes
  - Squamous cell carcinoma, conventional type
  - Spindle cell (sarcomatoid) squamous cell carcinoma
  - Basaloid squamous cell carcinoma
  - Acantholytic squamous cell carcinoma
  - Adenosquamous carcinoma
  - Papillary squamous cell carcinoma
  - Lymphoepithelial carcinoma
  - Verrucous carcinoma
  - Carcinoma cuniculatum

- Salivary gland-type carcinoma, specify type

- Neuroendocrine neoplasm, specify type

- Other, specify

### HISTOLOGICAL TUMOUR GRADE (Note 8)

(Applicable to conventional squamous cell carcinomas and minor salivary gland tumour)

- Not applicable
- Grade 1, well differentiated, low grade
- Grade 2, moderately differentiated, intermediate grade
- Grade 3, poorly differentiated, high grade
- Undifferentiated
- High grade transformation

Grading system used, specify

<p>| |</p>
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

- Cannot be assessed, specify

### DEPTH OF INVASION (Note 9)

(Resection specimens and excisional biopsies only; not applicable to incisional biopsies; applicable for squamous cell carcinoma only)

- ≤5 mm
- >5 mm and ≤10 mm
- >10 mm
- Cannot be assessed, specify

### PATTERN OF INVASIVE FRONT (Note 10)

(Resection specimens and excisional biopsies only; not applicable to incisional biopsies; applicable for squamous cell carcinoma only)

- Cohesive
- Non-cohesive
- Widely dispersed

### BONE INVASION (Note 11)

- Not applicable
- Not identified
- Present
  - Erosive (cortical)
  - Infiltrative (medullary involvement)
  - Indeterminate, specify reason

### LYMPHOVASCULAR INVASION (Note 12)

- Not identified
- Present
- Indeterminate, specify reason

### PERINEURAL INVASION (Note 13)

- Not identified
- Present
  - Nerve size, if known
  - mm
- Indeterminate, specify reason

For histological type of salivary gland-type carcinomas, refer to the Carcinomas of the major salivary glands dataset.
Carcinomas of the Oral Cavity

MARGIN STATUS (Note 14)

Invasive carcinoma

- Not involved
  - Distance of tumour from closest margin [ ] mm
  - Distance not assessable
    - Specify closest margin(s), if possible [ ]

- Involved
  - Specify margin(s), if possible [ ]

- Cannot be assessed, specify [ ]

Carcinoma in situ/high grade dysplasia

- Not applicable

- Not involved
  - Distance of carcinoma in situ/high grade dysplasia from closest margin [ ] mm
  - Distance not assessable
    - Specify closest margin(s), if possible [ ]

- Involved
  - Specify margin(s), if possible [ ]

- Cannot be assessed, specify [ ]

Note 14: High grade dysplasia is synonymous with moderate/severe dysplasia.

COEXISTENT PATHOLOGY (select all that apply) (Note 15)

- None identified
- Proliferative verrucous leukoplakia
- Fungal infection
- Dysplasia, specify grade [ ]
- HPV-associated dysplasia
- Submucous fibrosis
- Other, specify [ ]

ANCILLARY STUDIES (Note 16)

Neuroendocrine neoplasms (select all that apply)

- Not applicable
- Neuroendocrine markers, specify [ ]

- Cytokeratin(s), specify [ ]

- Ki-67 proliferation index [ ] %
- Rb [ ] Retained
- Deficient

PATHOLOGICAL STAGING (UICC TNM 8th edition) (Note 17)

TNM Descriptors (only if applicable) (select all that apply)

- m - multiple primary tumours
- r - recurrent
- y - during or following multimodality therapy

Primary tumour (pT)¹

- TX — Primary tumour cannot be assessed
- Tis — Carcinoma in situ
- T1 — Tumour 2 cm or less in greatest dimension and 5 mm or less depth of invasion
- T2 — Tumour 2 cm or less in greatest dimension and more than 5 mm depth of invasion or tumour more than 2 cm but not more than 4 cm in greatest dimension and depth of invasion no more than 10 mm
- T3 — Tumour more than 2 cm but not more than 4 cm in greatest dimension and depth of invasion more than 10 mm or tumour more than 4 cm in greatest dimension and not more than 10 mm depth of invasion
- T4a (Lip) — Tumour more than 4 cm in greatest dimension and more than 10 mm depth of invasion or tumour invades through cortical bone, inferior alveolar nerve, floor of mouth, or skin (of the chin or the nose)
- T4a (Oral cavity) — Tumour more than 4 cm in greatest dimension and more than 10 mm depth of invasion or tumour invades through the cortical bone of the mandible or maxilla or involves the maxillary sinus, or invades the skin of the face
- T4b (Lip and oral cavity) — Tumour invades masticator space, pterygoid plates, or skull base, or encases internal carotid artery


¹ Note that the results of neck (lymph node) dissection are derived from a separate dataset.
² TX should be used only if absolutely necessary.
³ Superficial erosion alone of bone/tooth socket by gingival primary is not sufficient to classify a tumour as T4a.
Definitions

CORE elements

CORE elements are those which are essential for the clinical management, staging or prognosis of the cancer. These elements will either have evidentiary support at Level III-2 or above (based on prognostic factors in the National Health and Medical Research Council (NHMRC) levels of evidence). In rare circumstances, where level III-2 evidence is not available an element may be made a CORE element where there is unanimous agreement in the Dataset Authoring Committee (DAC). An appropriate staging system e.g., Pathological TNM staging would normally be included as a CORE element.

Non-morphological testing e.g., molecular or immunohistochemical testing is a growing feature of cancer reporting. However, in many parts of the world this type of testing is limited by the available resources. In order to encourage the global adoption of ancillary tests for patient benefit, International Collaboration on Cancer Reporting (ICCR) includes the most relevant ancillary testing in ICCR Datasets as CORE elements, especially when they are necessary for the diagnosis. Where the technical capability does not yet exist, laboratories may consider temporarily using these data elements as NON-CORE items.

The summation of all Core elements is considered to be the minimum reporting standard for a specific cancer.

NON-CORE elements

NON-CORE elements are those which are unanimously agreed should be included in the dataset but are not supported by level III-2 evidence. These elements may be clinically important and recommended as good practice but are not yet validated or regularly used in patient management.

Key information other than that which is essential for clinical management, staging or prognosis of the cancer such as macroscopic observations and interpretation, which are fundamental to the histological diagnosis and conclusion e.g., macroscopic tumour details, may be included as either CORE or NON-CORE elements by consensus of the DAC.

Scope

The dataset has been developed for the reporting of resection and excisional biopsy specimens of malignancies of the oral cavity, including mucosal lip and tongue (mucosal carcinomas, minor salivary gland malignancies, and neuroendocrine tumours). For resections of recurrent disease, the reporting guide may be used pragmatically although some data elements may be not applicable nor assessable. Incisional biopsies and other biopsy specimens are not included in this dataset. Mucosal melanoma, lymphomas and sarcomas are dealt with in separate ICCR datasets. In addition, neck dissections and nodal excisions are dealt with in a separate ICCR dataset, and this dataset should be used in conjunction, where applicable.

For additional independent (multicentric) tumours, complete a separate dataset for each.

The second edition of this dataset includes changes to align the dataset with the World Health Organization (WHO) Classification of Head and Neck Tumours, 5th edition, 2024.
**Note 1 – Previous therapy** (Non-core)

There is no agreed upon system for grading tumour regression in oral squamous cell carcinoma (OSCC) that has been treated with previous therapy.\(^5\)

However, a history of previous radiotherapy and/or chemotherapy should be included as histologic changes related to the therapy such as necrosis may affect interpretation of the tumour.\(^6\)

↑ Back

**Note 2 – Operative procedure** (Core)

It is important to correlate the type of procedure (excisional biopsy or resection) with the material received for patient safety. Site-specific designations are required for accurate staging and for cancer registration. Modification of the resection, for example, partial, total should be described (e.g., hemi-glossectomy, partial glossectomy, hemi-mandibulectomy, segmental (partial) mandibulectomy, partial maxillectomy, selective neck dissection).\(^7,8\)

The exact surgical procedure may require discussion between the pathologist and surgeon.

↑ Back

**Note 3 – Specimen(s) submitted** (Core) and **Tumour site** (Core)

The anatomy and surgical interventions of the oral cavity are complex, and it is important to ensure accurate and precise communication between the pathologists and the treating and diagnostic team with respect to exact anatomic site of involvement, tumour laterality and specific operative procedures.\(^9-11\)

The protocol applies to all carcinomas arising at these sites (see Figure 1). For large cancers that involve more than one site, the primary site of involvement should be recorded.

Mucosal Lip. Begins at the junction of the wet and dry mucosa (vermilion border) that comes in contact with the opposing lip. The dry vermilion lip and vermilion border are staged using the cutaneous dataset.\(^12\)

Buccal Mucosa (Inner Cheek). Mucous membrane lining of the inner surface of the cheeks and lips of contact of the opposing lips to the line of attachment of mucosa of the upper and lower alveolar ridge and pterygomandibular raphe.

Lower Alveolar Ridge. Mucosa overlying the alveolar process of the mandible, which extends from the line of attachment of mucosa in the buccal vestibule to the line of free mucosa of the floor of the mouth. Posteriorly it extends to the ascending ramus of the mandible.

Upper Alveolar Ridge. Mucosa overlying the alveolar process of the maxilla, which extends from the line of attachment of mucosa in the upper gingival buccal vestibule to the junction of the hard palate. The posterior margin is the upper end of the pterygopalatine arch.
Floor of the Mouth. Semilunar space over the mylohyoid and hyoglossus muscles, extending from the inner surface of the lower alveolar ridge to the undersurface of the tongue. The posterior boundary is the base of the anterior pillar of the tonsil. It is divided into two sides of the submaxillary and sublingual salivary glands.

Hard Palate. This is the semilunar area between the upper alveolar ridge and the mucous membrane covering the palatine process of the maxillary palatine bones. It extends from the inner surface of the superior alveolar ridge to the posterior edge of the palatine bone.

Anterior Two-Thirds of the Tongue (Oral Tongue). The freely mobile portion of the tongue that extends anteriorly from the line of circumvallate papillae to the undersurface (ventral) of the tongue at the junction of the floor of the mouth. It includes the tip of tongue, lateral borders, dorsal surface and ventral tongue. The ventral tongue is listed as a separate tumour site in the ICCR reporting guide.

Retromolar trigone. A triangular shaped region extending distal from the mandibular third molar as the base and attaches to the hamulus of the medial pterygoid process of the sphenoid bone as the apex.

‘Not specified’ should be used rarely and only after good effort has been employed to obtain the requisite information.

Figure 1: Anatomic sites and subsites for lip and oral cavity.

- The vermilion/dry lip is considered cutaneous.
- The uvula and soft palate and tonsil are considered oropharynx.
Note 4 – Tumour focality (Non-core)

True multifocal or synchronous oral cavity carcinomas are rare. Patients with OSCC have an increased incidence (2-3%) of developing a second primary lesion, however, these are usually metachronous lesions. The theory of field cancerization whereby contiguous genetically altered areas of mucosa lead to the development of neoplasms have been supported by studies evaluating clonality and other molecular markers. Proliferative verrucous leukoplakia has the propensity for developing multifocal tumours. It is rare to have multiple tumours disconnected but not uncommon to have more than one squamous cell carcinoma (SCC) connected via dysplasia. The location, proximity to dysplastic epithelium, depth and nodal status remain important. Tumour focality is used for staging as well as clinical trials and treatment considerations.13-15

Note 5 – Tumour dimensions (Core and Non-core)

Tumour dimension is an important component in pathologic staging.16,17 If available, measurements are made on fresh tissue. The macroscopic diameter (in millimetres) should be used unless the histological extent is greater than macroscopically apparent, in which case the microscopic dimension is used. At times only microscopic evaluation differentiates what clinically appears to be tumour from what is actual invasion (not dysplasia or inflammation). At least the greatest tumour dimension should be reported; preferably all three dimensions should be evaluated. Measurements are made pragmatically, acknowledging distortion of tissues by fixation and processing.18

Note 6 – Block identification key (Non-core)

The origin/designation of all tissue blocks should be recorded. This information should ideally be documented in the final pathology report and is particularly important should the need for internal or external review arise. The reviewer needs to be clear about the origin of each block in order to provide an informed specialist opinion. If this information is not included in the final pathology report, it should be available on the laboratory computer system and relayed to the reviewing pathologist. It may be useful to have a digital image of the specimen and record of the origin of the tumour blocks in some cases.

Recording the origin/designation of tissue blocks also facilitates retrieval of blocks for further immunohistochemical or molecular analysis, research studies or clinical trials.
Note 7 – Histological tumour type (Core)

All tumours of the oral cavity should be given a type based on the most recent edition of the WHO Classification of Head and Neck Tumours, 5th edition, 2024 (Table 1). The major histologic tumour types of SCC as recognised by the WHO classification are SCC, conventional type, basaloid, papillary, spindle, adenosquamous, acantholytic, lymphoepithelial, verrucous carcinoma and carcinoma cuniculatum. Hybrid lesions such as verrucous carcinoma and SCC exist and should be recognised as it may affect prognosis. Subtypes should be assigned for both prognosis and cancer registry.

Salivary gland carcinoma histologic type essentially defines its biologic behaviour and thus influences prognosis, patterns of recurrence and thus clinical management. Some carcinoma types (i.e., basal cell adenocarcinoma, conventional acinic cell carcinoma) are more indolent with locoregional recurrence but low nodal and distant metastatic rates. For guidance on histological typing of minor salivary gland carcinomas, please refer to the ICCR Carcinomas of the major salivary gland dataset.

The classification and grading of neuroendocrine carcinomas (NEC) is discussed in Note 8 HISTOLOGICAL TUMOUR GRADE.

Table 1: World Health Organization classification of subtypes of squamous cell carcinoma of the oral cavity and mobile tongue.

<table>
<thead>
<tr>
<th>Descriptor</th>
<th>ICD-O codes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Epithelial tumours and lesions</strong></td>
<td></td>
</tr>
<tr>
<td>Squamous cell carcinoma, conventional type</td>
<td>8070/3</td>
</tr>
<tr>
<td>Spindle cell (sarcomatoid) squamous cell carcinoma</td>
<td>8074/3</td>
</tr>
<tr>
<td>Basaloid squamous cell carcinoma</td>
<td>8083/3</td>
</tr>
<tr>
<td>Acantholytic squamous cell carcinoma</td>
<td>8075/3</td>
</tr>
<tr>
<td>Adenosquamous carcinoma</td>
<td>8560/3</td>
</tr>
<tr>
<td>Papillary squamous cell carcinoma</td>
<td>8052/3</td>
</tr>
<tr>
<td>Lymphoepithelial carcinoma</td>
<td>8082/3</td>
</tr>
<tr>
<td>Verrucous carcinoma</td>
<td>8051/3</td>
</tr>
<tr>
<td>Carcinoma cuniculatum</td>
<td>8071/3</td>
</tr>
<tr>
<td><strong>Epithelial neuroendocrine neoplasms</strong></td>
<td></td>
</tr>
<tr>
<td>Small cell neuroendocrine carcinoma</td>
<td>8041/3</td>
</tr>
<tr>
<td>Large cell neuroendocrine carcinoma</td>
<td>8013/3</td>
</tr>
<tr>
<td>Carcinoma mixed with small cell neuroendocrine carcinoma</td>
<td>8045/3</td>
</tr>
<tr>
<td>Carcinoma mixed with large cell neuroendocrine carcinoma</td>
<td>8013/3</td>
</tr>
</tbody>
</table>

These morphology codes are from the International Classification of Diseases for Oncology, third edition, second revision (ICD-O-3.2). Behaviour is coded /0 for benign tumours; /1 for unspecified, borderline, or uncertain behaviour: /2 for carcinoma in situ and grade III intraepithelial neoplasia; /3 for malignant tumours, primary site: and /6 for malignant tumours, metastatic site. Behaviour code /6 is not generally used by cancer registries.

This terminology is synonymous with the ICD-O terminology of combined small/large cell neuroendocrine carcinomas.

Note 8 – Histological tumour grade (Core)

Based on the WHO classifications, three histologic grades of SCC, conventional type are used: well, moderately or poorly differentiated.4 The most aggressive or highest grade should be recorded if the tumour has a varied histology. Grading requires the assessment of keratinisation, mitotic activity, cellular and nuclear pleomorphism, pattern of invasion and host response.7,25-27 SCC subtypes are not graded. Still, several grading systems for each tumour type are available, with differing merits, and as such, recording which system has been applied is more clinically meaningfully (use ‘specify’ to state the system used).

Grading of minor salivary gland tumours follows the criteria for major salivary gland tumours.22,23

Neuroendocrine neoplasms, as newly defined,4 include paraganglioma/pheochromocytoma, neuroendocrine tumours, and NECs. Neuroendocrine tumours are separated into grades (1, 2, and 3) based on mitotic rate and Ki-67 proliferation indices, but these criteria are not yet fully developed for each of the anatomic sites in the head and neck. At present, the general cutoffs are: grade 1: <2 mitoses/2 millimetre (mm)² and <2% Ki-67 proliferation index; grade 2: ≥2-10 mitoses/2 mm² and 2-20% Ki-67 proliferation index; grade 3: ≥11 mitoses/2 mm² and >20% Ki-67 proliferation index.28,29 Further, NECs are separated into small cell and large cell categories, showing tumour necrosis, >10 mitoses/2 mm² and >20% Ki-67 proliferation index,28,30-32 with universal Rb1 loss and common p53 overexpression.33 At present, the site, tumour category, and grade should be reported, with additional advances in this field incorporated when validated further.

Note 9 – Depth of invasion (Core)

Depth of invasion (DOI) in OSCC, particularly of the tongue, has been identified as an important prognostic indicator, and is therefore a core element. The Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) TNM staging systems incorporate DOI in determining the tumour stage (T).16,17,34 DOI increases T by 1 step for every 5 mm, whereby T1 is tumour ≤20 mm (≤2 centimetres (cm)) and DOI ≤5 mm, T2 is tumour ≤20 mm (≤2 cm) and DOI >5 mm and ≤10 mm, T3 tumour is >20 mm (>2 cm) and ≤40 mm (≤4 cm) and >10 mm DOI and T4a is tumour >40 mm (>4 cm) or any tumour >10 mm DOI. DOI measures the invasiveness of the carcinoma. To measure DOI, the basement membrane is identified, and an imaginary line is drawn across the tumour. A vertical or ‘plumb line’ extends to the deepest part of the tumour which represents the DOI. It is important to note that DOI is not synonymous with tumour thickness. An exophytic tumour (Figure 2A) may be thicker than an ulcerative tumour (Figure 2B), but the DOI of the ulcerative lesion may be greater.35,36

The maximum DOI should be recorded as core and the discussion should include how/why DOI is different than tumour thickness.18,37-39
Figure 2A: Measuring depth of invasion. © 2024 International Collaboration on Cancer Reporting Limited (ICCR).

Figure 2B: Measuring depth of invasion. © 2024 International Collaboration on Cancer Reporting Limited (ICCR).
Note 10 – Pattern of invasive front (Core)

The pattern of invasion in OSCC has proven prognostic value and should be reported as cohesive or non-cohesive (Figure 3).\textsuperscript{25,40-43} It is important to evaluate the most complex area of tumour-stroma interface (‘worst’ area), usually at the advancing edge, and ideally assessment should only be made on resection specimens or excisional biopsies. Acknowledgement is made that at times non-surgical treatment decisions are made on incisional biopsy specimens only and consequently the best assessment of pattern of invasion should be noted. Cohesive invasion is defined as broad sheets of cancer cells and/or tumour nests of >15 tumour cells. Non-cohesive invasion shows a spectrum of appearances that includes narrow strands, small groups of ≤15 tumour cells and single infiltrating tumour cells.\textsuperscript{35,36} For stage T1/T2 OSCC, particularly those arising in the tongue, there is evidence that tumour satellites localised ≥1 mm away from the main tumour or nearest satellite (worst pattern of invasion WPOI-5) is a valid adverse prognostic factor.\textsuperscript{25,40-42,44}

Additionally, tumour budding has emerged as a promising biomarker in various carcinomas, with early evidence suggesting that it is an independent adverse prognostic factor in carcinoma of the oral cavity.\textsuperscript{45-52}

Tumour budding is defined as single tumour cells or clusters of up to four tumour cells at the invasive tumour front. There is no consensus yet how it should be assessed and graded in oral carcinoma. It has been recommended to count the number of buds in 2 mm\textsuperscript{2} high power field (HPF) (x40) after scanning 10 HPFs in areas showing maximal budding.\textsuperscript{53} Budding activity is graded as low if 1 to 14 buds per 2 mm\textsuperscript{2} and high if ≥15 buds per 2 mm\textsuperscript{2} are counted.

![Pattern of Invasion](image_url)

*Figure 3: Pattern of Invasive front.* © 2024 International Collaboration on Cancer Reporting Limited (ICCR).

↑ Back
Note 11 – Bone invasion (Core)

Infiltrative bone involvement by SCC correlates with a worse prognosis. Bone invasion may be a macroscopic feature, however sampling through the involved bone for histologic examination should be performed to obtain histologic evidence. The presence of bone invasion affects tumour staging and patients with bone invasion often have a worse prognosis. It is important to distinguish superficial cortical bone erosion from infiltrative invasion to the medullary bone as this is critical in accurate tumour staging. If bone is resected, then bone margins should be recorded.54

↑ Back

Note 12 – Lymphovascular invasion (Core)

There is a need to distinguish between intravascular tumour embolization and retraction artefact. Positive lymphovascular invasion is a risk factor for decreased overall survival and should be reported only when tumour emboli are identified within endothelial lined spaces. No distinction between venous channels and small lymphatics is required.27,55,56

Cases that are still equivocal after taking additional steps may be reported as ‘indeterminate’ for lymphovascular invasion, but this designation should be sparingly used, and it is useful to provide the reason in a comment in the report.

↑ Back

Note 13 – Perineural invasion (Core and Non-core)

Perineural invasion is associated with a worse prognosis, regardless of nerve size and should be recorded. The presence or absence of perineural and/or endoneural/intraneural invasion may impact subsequent therapy and prognosis.7,25,27,57

↑ Back

Note 14 – Margin status (Core)

All surgical margins should be measured in millimetres histologically for both mucosal and deep margins. In the comments section, acknowledgement should be made how the surgical margin was measured. For example, if the margin was submitted from the tumour bed margin at the time of the operative procedure rather than from the surgical specimen.58-60 The presence of severe dysplasia/carcinoma in situ at the margin is associated with an increased risk of local recurrence and this should be recorded. The definition of a ‘close’ margin is not standardised but in the oral cavity from a surgical point of view >5 mm is clear, and 1-5 mm is close while <1 mm is involved. Acknowledgement is made of fixation and processing distortion on measurements which may cause tissue shrinkage including the surgical margin.61 Acknowledgement is also made of any laser or electrocautery associated tissue distortion such as cellular and nuclear polymorphism, nuclear hyperchromatism, epithelial cell separation, collagen denaturation, etc. on measurements including the surgical margin.62 Any bone resection margins should be identified and comment on the presence or absence of carcinoma at these margins should be provided.7,54 Dysplastic changes include abnormal cellular organisation, increased mitotic activity, and nuclear enlargement with pleomorphism.7,25,63,64 Although
terminology varies, using the 2024 WHO criteria for oral dysplasia, dysplasia limited to the lower one-third of the epithelium is generally referred to as mild dysplasia, although this can undercall higher dysplasia grades. Moderate dysplasia is defined as cytological atypia extending to the middle third of the epithelium and severe dysplasia extends to the upper third of the epithelium. Carcinoma in situ is considered synonymous with severe dysplasia.

Reporting of surgical margins for carcinomas of the minor salivary glands should follow those used for SCC of oral cavity.

↑ Back

**Note 15 – Coexistent pathology (Non-core)**

The most common sites of dysplasia with the highest risk of malignant transformation are lateral and ventral tongue, floor of mouth, and lower lip. Dysplastic changes include abnormal cellular organisation, increased mitotic activity including abnormal forms, and nuclear enlargement with pleomorphism. Although terminology varies, dysplasia limited to the lower one-third of the epithelium is generally referred to as mild dysplasia (low grade dysplasia), dysplasia limited to the lower two-thirds as moderate dysplasia and dysplasia involving the full thickness as severe dysplasia/carcinoma in situ. However, when moderate dysplasia has marked cytologic atypia, then often the lesion will be upgraded to severe dysplasia. A recently described subset of oral dysplasia is positive for high risk human papillomavirus (HPV). The epithelium exhibits full-thickness dysplastic changes with karyorrhexis, and apoptosis and the cells are strongly positive for p16 by immunohistochemistry but this should not be used as a surrogate marker for HPV in the oral cavity.

Proliferative verrucous leukoplakia (PVL) is a distinct form of oral potentially malignant disorder (OPMD) of unknown etiology with a multifocal presentation and a progressive course with high recurrence rates and malignant transformation in as many as 70% of cases. This diagnosis requires adequate clinical information.

Subepithelial fibrosis is a characteristic of oral submucous fibrosis and increased fibrosis is associated with an increased risk of epithelial dysplasia.

Some inherited genetic mutations are associated with a higher risk of oral cancer development, including Fanconi anemia, Li-Fraumeni syndrome and dyskeratosis congenita.

Patients with graft versus host disease resulting from allogenic hematopoietic stem cell transplantation have an increased risk of developing oral cancer.

Care must be taken to rule out reactive atypia which can be seen in epithelium adjacent to ulcers and with fungal infections.

↑ Back
Note 16 – Ancillary studies (Core and Non-core)

For neuroendocrine neoplasms core elements are neuroendocrine markers, epithelial markers, and Ki-67 proliferation index. The diagnosis of neuroendocrine neoplasms (specifically NETs and NECs) must be confirmed immunohistochemically, with positive reaction for neuroendocrine markers (synaptophysin, chromogranin, INSM1) and for epithelial markers (pancytokeratin, cytokeratin). Furthermore, a proliferation index as determined by Ki-67 immunohistochemical analysis is recommended for grading all NETs, helping to confirm NECs, and p53 and Rb1 may be helpful in the distinction between NET and NEC, especially G3 NET from NEC.29,33,70

In most cases, further studies are not required for diagnosis of other tumours. Epithelial immunohistochemical markers may be required for poorly differentiated or spindle cell carcinoma including AE1/AE3, CK5/6, p63 and p40.71 Lymphoepithelial SCC in the oral cavity is rare and although not all cases are Epstein-Barr virus (EBV)-positive, EBV-encoded small RNAs (EBERs) studies are indicated.72 There is currently no role for routine HPV high risk type testing in OSCC.19,71 HPV-associated epithelial dysplasia requires in-situ hybridization/PCR confirmation.19

Programmed cell death-ligand 1 (PD-L1) expression has been used as predictive biomarker for checkpoint inhibitor therapy since the anti programmed cell death-1 receptor (PD-1) antibodies, nivolumab and pembrolizumab, have been approved for the treatment of patients with recurrent and/or unresectable metastatic head and neck SCC,73-76 with various cutoffs of expression associated with betters responses, although not in all patients.77

↑ Back

Note 17 – Pathological staging (Core)

By UICC/AJCC convention,16,17 the designation ‘T’ refers to a primary tumour that has not been previously treated. The symbol ‘p’ refers to the pathologic classification of the stage, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumour adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. There is no pathologic M0 category as this designation requires clinical evaluation and imaging. Clinical classification (cTNM) is usually carried out by the evaluating clinician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathological staging is usually performed after surgical resection of the primary tumour and depends on documentation of the anatomic extent of disease, whether or not the primary tumour has been completely removed. If a biopsied tumour is not resected for any reason (e.g., when technically unfeasible) and if the highest T and N categories or the M1 category of the tumour can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied even though total removal of the primary cancer was not performed.

TNM Descriptors

For identification of special cases of TNM or pTNM classifications, the ‘m’ suffix and ‘y’ and ‘r’ prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The ‘m’ suffix indicates the presence of multiple primary tumours in a single site and is recorded in parentheses: pT(m)NM.
The ‘y’ prefix indicates those cases in which classification is performed during or following initial multimodality therapy (i.e., neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a ‘y’ prefix. The ycTNM or ypTNM categorises the extent of tumour actually present at the time of that examination. The ‘y’ categorisation is not an estimate of tumour prior to multimodality therapy (i.e., before initiation of neoadjuvant therapy).

The ‘r’ prefix indicates a recurrent tumour when staged after a documented disease-free interval, and is identified by the ‘r’ prefix: rTNM.

For the pN classification of regional lymph nodes, see ICCR Nodal excisions and neck dissection specimens dataset.³

Reporting of pathological staging categories (pT, pN, pM) is based on the evidence available to the pathologist at the time of reporting. As indicated in UICC TNM8 and AJCC TNM8,¹⁶,¹⁷ the final stage grouping of a patient’s tumour is based on a combination of pathological staging and other clinical and imaging information.

Pathological staging should not be reported if the submitted specimen is insufficient for definitive staging, especially with biopsy samples (core needle, incisional or excisional). Staging is based on the submitted resection, and even if there is grossly residual disease or there is tumour at the margin, pT staging should only be reported on findings in the resection specimen and/or at operation.¹⁷

The reference document TNM Supplement: A commentary on uniform use, 5th Edition (C Wittekind et al. editors) may be of assistance when staging.⁷⁸

References

1 Merlin T, Weston A and Tooher R (2009). Extending an evidence hierarchy to include topics other than treatment: revising the Australian 'levels of evidence'. BMC Med Res Methodol 9:34.


47 Hong KO, Oh KY, Shin WJ, Yoon HJ, Lee JI and Hong SD (2018). Tumor budding is associated with poor prognosis of oral squamous cell carcinoma and histologically represents an epithelial-mesenchymal transition process. *Hum Pathol* 80:123-129.


